Literature DB >> 19860785

Day 1 postoperative intraocular pressure spike in vitreoretinal surgery (VDOP1).

Roger Wong1, Bhaskar Gupta, Thomas H Williamson, D Alistair H Laidlaw.   

Abstract

PURPOSE: To classify the clinical characteristics that might identify patients who may not require next-day follow-up following routine vitreoretinal intervention.
METHODS: Prospective case series.
RESULTS: The only statistically significant factors for raised intraocular pressure (IOP) were gas tamponade and preoperative raised IOP. 44.7% (17/38) of patients with preoperative IOP ≥ 20 mmHg had postoperative IOP ≥ 30 mmHg while 8.6% (17/197) of patients with preoperative IOP < 20 mmHg had postoperative IOP ≥ 30 mmHg (p = 0.0001). Phacoemulsification did not increase risk for a postoperative IOP spike. There was a 20-21% risk of postoperative IOP > 30 mmHg for patients with gas tamponade. All patients with no tamponade with IOP > 30 mmHg had preoperative IOP ≥ 20 mmHg.
CONCLUSION: Uncomplicated vitreoretinal procedures with preoperative IOP of< 20 mmHg and no gas tamponade are unlikely to have uncontrolled IOP spike at day 1.
© 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860785     DOI: 10.1111/j.1755-3768.2009.01703.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  10 in total

1.  Intraocular pressure is not the only important postoperative variable following vitrectomy.

Authors:  P Alexander; L Michaels; R S Newsom
Journal:  Eye (Lond)       Date:  2016-02-05       Impact factor: 3.775

2.  Is day-1 postoperative review necessary after pars plana vitrectomy?

Authors:  P Alexander; L Michaels; R Newsom
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

3.  Primary rhegmatogenous retinal detachment: evaluation of a minimally restricted face-down positioning after pars plana vitrectomy and gas tamponade.

Authors:  Kiichiro Kusaba; Kotaro Tsuboi; Tsuneaki Handa; Yukihiko Shiraki; Takuya Kataoka; Motohiro Kmaei
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

4.  Perioperative changes of the intraocular pressure during the treatment of epiretinal membrane by using 25- or 27-gauge sutureless vitrectomy without gas tamponade.

Authors:  Hirotsugu Takashina; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Clin Ophthalmol       Date:  2017-04-19

5.  Ex vivo biophysical characterization of a hydrogel-based artificial vitreous substitute.

Authors:  Kai Januschowski; Sven Schnichels; José Hurst; Christine Hohenadl; Charlotte Reither; Annekatrin Rickmann; Lisa Pohl; Karl-Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

6.  Supine positioning after vitrectomy for rhegmatogenous retinal detachments with inferior retinal breaks.

Authors:  Amr Mohammed Elsayed Abdelkader; Hossam Youssef Abouelkheir
Journal:  Int J Retina Vitreous       Date:  2020-09-14

7.  Long-Term Biocompatibility of a Highly Viscously Thiol-Modified Cross-Linked Hyaluronate as a Novel Vitreous Body Substitute.

Authors:  Jose Hurst; Annekatrin Rickmann; Nele Heider; Christine Hohenadl; Charlotte Reither; Andreas Schatz; Sven Schnichels; Kai Januschowski; Martin S Spitzer
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

8.  Outcome of 2 cc pure sulfur hexafluoride gas tamponade for macular hole surgery.

Authors:  Naresh B Kannan; Olukorede O Adenuga; Karthik Kumar; Kim Ramasamy
Journal:  BMC Ophthalmol       Date:  2016-06-03       Impact factor: 2.209

9.  Vitrectomy without prone positioning for rhegmatogenous retinal detachments in eyes with inferior retinal breaks.

Authors:  Nobuhiko Shiraki; Susumu Sakimoto; Hirokazu Sakaguchi; Kentaro Nishida; Kohji Nishida; Motohiro Kamei
Journal:  PLoS One       Date:  2018-01-26       Impact factor: 3.240

10.  Case Series of Inappropriate Concentration of Intraocular Sulfur Hexafluoride.

Authors:  Piotr Kanclerz; Andrzej Grzybowski
Journal:  Case Rep Ophthalmol       Date:  2018-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.